Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2019 07:49 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia

LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the...
April 03, 2019 10:30 ET | Source: Seatrade

What to Expect at Seatrade Cruise Global 2019

NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Seatrade Cruise Global, the cruise industry’s leading annual business-to-business event, will feature 200 new exhibitors at this year’s record-breaking...
March 04, 2019 06:30 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present New Data on AUTO1 at the American Association of Cancer Research (AACR) Annual Meeting 2019

LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
February 28, 2019 15:20 ET | Source: Bell and Howell

Retailers Select Bell and Howell for Supply Chain Innovation Award

Durham, NC, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Bell and Howell was awarded the “Retailers’ Choice” at the 2019 (R)Tech Supply Chain Awards by the Retail Industry Leaders Association (RILA) at...
October 01, 2018 10:45 ET | Source: Investorideas.com

Breaking News – DEA Removes CBD as a Schedule 1 Drug. CBD Stocks to Watch - GW Pharma, India Globalization Capital, Inc., Tilray Inc, American Premium Water Corp

POINT ROBERTS, Wash., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a global news source covering leading equity sectors, including marijuana and hemp, releases an industry snapshot focusing...
June 15, 2018 01:30 ET | Source: Erytech Pharma S.A.

ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic...
May 14, 2018 16:30 ET | Source: Erytech Pharma S.A.

ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update

Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
April 24, 2018 16:30 ET | Source: Erytech Pharma S.A.

ERYTECH annonce le dépôt de son Document de Référence 2017 et de son Form 20-F 2017

LYON, France, 24 avr. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire...
April 24, 2018 16:30 ET | Source: Erytech Pharma S.A.

ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

LYON, France, April 24, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of...
April 12, 2018 01:30 ET | Source: Erytech Pharma S.A.

ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and New Pre-clinical Data at AACR 2018

LYON, France, April 12, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...